Sk Biopharmaceuticals Co Ltd (326030) — Capital Reinvestment Ratio
Sk Biopharmaceuticals Co Ltd (326030) has a Capital Reinvestment Ratio of 0.31x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩87.00 Billion) in capital expenditures (₩26.55 Billion). See debt-free asset ratio of Sk Biopharmaceuticals Co Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sk Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2025)
This chart tracks Sk Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 2 annual periods. Check how aggressively does Sk Biopharmaceuticals Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd (2024–2025)
Year-by-year Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd from 2024 to 2025. For live market cap and broader valuation context, see Sk Biopharmaceuticals Co Ltd (326030) total market value.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | ₩176.33 Billion | ₩29.51 Billion | ▲ +18.3% |
| 2024 | 0.14x | ₩94.90 Billion | ₩13.42 Billion | — |